About US
Contact us
-
Novartis teams up with Microsoft for AI drug developmentNovartis has allied with Microsoft to leverage the latter’s artificial intelligence (AI) technology for the discovery, development and commercialisation of medicines. Under the multi-year collaborati2019/9/24
-
J&J resolves opioid lawsuits in two Ohio counties for $20.4mUS pharma giant Johnson & Johnson (J&J) has announced the resolution and settlement of all opioid-based lawsuits with two Ohio counties, Cuyahoga and Summit, for $10m. This means the company2019/9/23
-
Roche’s Tecentriq performs well in untreated bladder cancerRoche has announced positive results of Tecentriq (atezolizumab) combined with platinum-based chemotherapy in a Phase III study of patients with previously untreated advanced or metastatic urothelial2019/9/23
-
Sobi to purchase Dova Pharmaceuticals in $915m dealSwedish Orphan Biovitrum AB (Sobi) has agreed to acquire US-based Dova Pharmaceuticals in a transaction valued up to $915m. Dova Pharmaceuticals was established in 2016 to commercialise Doptelet, a s2019/9/20
-
Cheplapharm to acquire Losec’s global commercial rights for $243mGerman pharmaceutical company Cheplapharm Arzneimittel has signed an agreement to purchase global commercial rights for Losec (omeprazole) from AstraZeneca for $243m. Under the agreement, Cheplapharm2019/9/20
-
Moberg Pharma signs deal with Taisho for MOB-015 developmentSwedish company Moberg Pharma has signed an agreement with Taisho Pharmaceutical towards the development, registration and commercialisation of MOB-015 in Japan. MOB-015 is a topical treatment of ony2019/9/19
-
AstraZeneca and Merck announce full results for PARP inhibitor LynparzaAstraZeneca and Merck have presented full progression-free survival (PFS) results from the Phase III PAOLA-1 study of their PARP inhibitor Lynparza (olaparib) in newly-diagnosed ovarian cancer patien2019/9/19
-
Kinoxis secures US grant for opioid withdrawal treatmentThe US National Institutes of Health (NIH) has awarded a grant of up to $4.6m to University of Sydney spinout Kinoxis Therapeutics to support the development of a potential treatment for opioid withd2019/9/18
-
Roche’s Rituxan secures approval for first paediatric indicationRoche has secured approval from the US Food and Drug Administration (FDA) for Rituxan (rituximab) for children with two rare blood vessel disorders. Rituxan, in combination with glucocorticoids, ha2019/9/18
-
Roche’s Rituxan secures approval for first paediatric indication2019/9/19